Skip to main content
SpringerLink
Log in

Lisdexamfetamine: A Review in Binge Eating Disorder

  • Adis Drug Evaluation
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Oral lisdexamfetamine dimesylate (Vyvanse®; lisdexamfetamine), a prodrug of dextroamfetamine, is currently the only drug to be approved in the USA for the treatment of moderate to severe binge eating disorder (BED) in adult patients. Its approval was based on the results of two pivotal short-term (12 weeks) phase III studies, which showed a significantly greater reduction in binge eating days/week at the end of the study with lisdexamfetamine 50–70 mg/day than with placebo. The findings of these studies have been supported and extended by the results of longer-term (≤ 52 weeks) phase III studies, including one with a randomized 26-week withdrawal phase, which showed that lisdexamfetamine markedly reduced the risk of BED relapse relative to placebo. Lisdexamfetamine was generally well tolerated in clinical trials in patients with moderate to severe BED, with a tolerability profile similar to that observed in ADHD patients; most treatment-emergent adverse events (TEAEs) were of mild or moderate intensity. The most common TEAEs in phase III trials included dry mouth, headache and insomnia; TEAEs infrequently led to study drug discontinuation. In conclusion, lisdexamfetamine 50–70 mg/day is an effective and generally well tolerated option for treating moderate to severe BED in adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brownley KA, Peat CM, La Via M, et al. Pharmacological approaches to the management of binge eating disorder. Drugs. 2015;75(1):9–32.

    Article  CAS  PubMed  Google Scholar 

  2. Wilfley DE, Citrome L, Herman BK. Characteristics of binge eating disorder in relation to diagnostic criteria. Neuropsychiatr Dis Treat. 2016;12:2213–23.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Agh T, Kovacs G, Pawaskar M, et al. Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review. Eat Weight Disord. 2015;20(1):1–12.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dakanalis A, Riva G, Serino S, et al. Classifying adults with binge eating disorder based on severity levels. Eur Eat Disord Rev. 2017;25(4):268–74.

    Article  PubMed  Google Scholar 

  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM–5). 2017. https://www.psychiatry.org/. Accessed 15 Sep.

  6. Guerdjikova AI, Mori N, Casuto LS, et al. Novel pharmacologic treatment in acute binge eating disorder—role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016;12:833–41.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Agh T, Kovacs G, Supina D, et al. A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. Eat Weight Disord. 2016;21(3):353–64.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Agh T, Pawaskar M, Nagy B, et al. The cost effectiveness of lisdexamfetamine dimesylate for the treatment of binge eating disorder in the USA. Clin Drug Investig. 2016;36(4):305–12.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: a systematic review and meta-analysis. Ann Intern Med. 2016;165(6):409–20.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Shire US Inc. Vyvanse® (lisdexamfetamine dimesylate): US prescribing information 2017;2017.

  11. Frampton JE. Lisdexamfetamine: a review in ADHD in adults. CNS Drugs. 2016;30(4):343–54.

    Article  CAS  PubMed  Google Scholar 

  12. Vickers SP, Hackett D, Murray F, et al. Effects of lisdexamfetamine in a rat model of binge-eating. J Psychopharmacol (Oxf). 2015;29(12):1290–307.

    Article  CAS  Google Scholar 

  13. Vickers SP, Goddard S, Brammer RJ, et al. Investigation of impulsivity in binge-eating rats in a delay-discounting task and its prevention by the d-amphetamine prodrug, lisdexamfetamine. J Psychopharmacol (Oxf). 2017;31(6):784–97.

    Article  Google Scholar 

  14. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig. 2008;28(12):745–55.

    Article  CAS  PubMed  Google Scholar 

  15. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235–46.

    Article  PubMed  Google Scholar 

  16. McElroy SL, Hudson J, Ferreira-Cornwell MC, et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251–60.

    Article  CAS  PubMed  Google Scholar 

  17. Hudson JI, McElroy SL, Ferreira-Cornwell MC, et al. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2017. https://doi.org/10.1001/jamapsychiatry.2017.1889.

    PubMed Central  Google Scholar 

  18. McElroy SL, Hudson JI, Gasior M, et al. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge eating disorder. Int J Eat Disord. 2017;50(8):884–92.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Gasior M, Hudson J, Quintero J, et al. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. J Clin Psychopharmacol. 2017;37(3):315–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–73.

    Article  CAS  PubMed  Google Scholar 

  21. Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Carano A, De Berardis D, Campanella D, et al. Alexithymia and suicide ideation in a sample of patients with binge eating disorder. J Psychiatr Pract. 2012;18(1):5–11.

    Article  PubMed  Google Scholar 

  23. Preti A, Rocchi MB, Sisti D, et al. A comprehensive meta-analysis of the risk of suicide in eating disorders. Acta Psychiatr Scand. 2011;124(1):6–17.

    Article  CAS  PubMed  Google Scholar 

  24. Yager J, Devlin MJ, Halmi KA, et al. Guideline watch (August 2012): practice guideline for the treatment of patients with eating disorders. Focus. 2014;12(4):416–31.

    Article  Google Scholar 

  25. Yager J, Devlin MJ, Halmi KA, et al. Treatment of patients with eating disorders, third edition. American Psychiatric Association. Am J Psychiatry. 2006;163(Suppl 7):4–54.

  26. McElroy SL. Pharmacologic treatments for binge-eating disorder. J Clin Psychiatry. 2017;78(Suppl 1):14–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of lisdexamfetamine was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Young-A. Heo & Sean T. Duggan

Authors
  1. Young-A. Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean T. Duggan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-A. Heo.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Young-A Heo and Sean Duggan are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/2DACF0607E38664B.

Additional information

The manuscript was reviewed by: M.C. Mancini, Obesity and Metabolic Syndrome Unit, Endocrinology and Metabolism Service, Clinics Hospital, Sao Paulo University Medical School, Sao Paulo, Brazil; J.L. Roerig, Department of Psychiatry and Behavioral Science, School of Medicine and Health Sciences, University of North Dakota, Fargo, ND, USA; S. Touyz, School of Psychology, University of Sydney, Sydney, Australia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heo, YA., Duggan, S.T. Lisdexamfetamine: A Review in Binge Eating Disorder. CNS Drugs 31, 1015–1022 (2017). https://doi.org/10.1007/s40263-017-0477-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-017-0477-1

Search

Navigation